2022
Dasiglucagon demonstrates reduced costs in the treatment of severe hypoglycemia in a budget impact model
Hinahara J, Weinzimer SA, Bromley ER, Goss TF, Kendall DM, Hammer M. Dasiglucagon demonstrates reduced costs in the treatment of severe hypoglycemia in a budget impact model. Journal Of Managed Care & Specialty Pharmacy 2022, 28: 10.18553/jmcp.2022.28.4.461. PMID: 35332789, PMCID: PMC10373001, DOI: 10.18553/jmcp.2022.28.4.461.Peer-Reviewed Original ResearchConceptsBudget impact modelHealth care resource utilizationSevere hypoglycemiaSH eventsGlucagon treatmentNasal glucagonUS commercial health planLower total health care costsSuccessful administrationTotal direct medical costsTotal health care costsPlasma glucose recoveryEmergency department visitsSevere hypoglycemic eventsInitial treatment successDirect medical costsCommercial health plansType 2 diabetesHealth care costsHealth economic modelEmergency medical servicesNative glucagonGlucagon analogsInjectable glucagonPrompt administration
2020
Precision Dosing of Rapid-Acting Insulin Matters
Aanstoot HJ, Rodriguez H, Weinzimer S, Vint N, Koeneman L. Precision Dosing of Rapid-Acting Insulin Matters. Diabetes Technology & Therapeutics 2020, 22: 346-351. PMID: 32125891, DOI: 10.1089/dia.2019.0374.Peer-Reviewed Original ResearchConceptsGood glycemic controlGlycemic controlHalf-unit insulin pensInsulin pensDiabetes managementInsulin deliveryStringent glycemic controlInadequate glycemic controlType 2 diabetesType 1 diabetesPrecision of dosingDelivery devicesInsulin delivery devicesInsulin therapyGeriatric patientsHypoglycemic eventsPatient preferencesFlexible dosingPhysical activityDosingLiterature searchPrecision dosingDiabetesInsulinCorrective doses
2017
Standardizing Clinically Meaningful Outcome Measures Beyond HbA1c for Type 1 Diabetes: A Consensus Report of the American Association of Clinical Endocrinologists, the American Association of Diabetes Educators, the American Diabetes Association, the Endocrine Society, JDRF International, The Leona M. and Harry B. Helmsley Charitable Trust, the Pediatric Endocrine Society, and the T1D Exchange
Agiostratidou G, Anhalt H, Ball D, Blonde L, Gourgari E, Harriman KN, Kowalski AJ, Madden P, McAuliffe-Fogarty AH, McElwee-Malloy M, Peters A, Raman S, Reifschneider K, Rubin K, Weinzimer SA. Standardizing Clinically Meaningful Outcome Measures Beyond HbA1c for Type 1 Diabetes: A Consensus Report of the American Association of Clinical Endocrinologists, the American Association of Diabetes Educators, the American Diabetes Association, the Endocrine Society, JDRF International, The Leona M. and Harry B. Helmsley Charitable Trust, the Pediatric Endocrine Society, and the T1D Exchange. Diabetes Care 2017, 40: 1622-1630. PMID: 29162582, PMCID: PMC5864122, DOI: 10.2337/dc17-1624.Peer-Reviewed Original ResearchConceptsPatient-reported outcomesType 1 diabetesAmerican Diabetes AssociationPediatric Endocrine SocietyDiabetic ketoacidosisEndocrine SocietyClinical EndocrinologistsPriority outcomesDiabetes AssociationT1D ExchangeHarry B. Helmsley Charitable TrustDiabetes educatorsLong-term clinical impactType 1American AssociationType 2 diabetesSteering CommitteeLeona M.Helmsley Charitable TrustMeaningful outcome measuresType 1 diabetes outcomesAdvisory Committee
2004
Diabetes Mellitus in Children and Adolescents
Weinzimer S, Tamborlane W. Diabetes Mellitus in Children and Adolescents. 2004 DOI: 10.1002/0470862092.d0809.Peer-Reviewed Original ResearchDiabetes mellitusNormal glucose controlRoutine clinical practiceSpecific clinical presentationType 2 diabetesType 1 diabetesQuality of lifeOutpatient managementClinical presentationTreatment algorithmGlucose controlDifferential diagnosisClinical practiceMellitusDiabetesInsulin deliveryPresent unique challengesChildrenArtificial pancreasDiagnosisTreatmentUnique challengesPancreasPrevalenceClinicians